Tirzepatide targets both GLP-1 and GIP receptors , providing appetite suppression through two pathways instead of one
References Ozempic- semaglutide injection, solution [package insert]
placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes
Common questions Orders placed before 2pm CT ship the same business day from our US facility
Recommendations include 200-250 minutes of exercise weekly (combination of cardio and resistance), daily food tracking with calorie targets, weekly weigh-ins with predetermined action thresholds, and structured meal planning
Adequate magnesium intake (300400 mg daily for adults) supports cardiovascular function and glucose metabolism, both relevant to weight loss success
